HRP20150064T1 - Kombinacija inzulina i derivata triazina te uporaba iste u lijeäśenju dijabetesa - Google Patents
Kombinacija inzulina i derivata triazina te uporaba iste u lijeäśenju dijabetesa Download PDFInfo
- Publication number
- HRP20150064T1 HRP20150064T1 HRP20150064AT HRP20150064T HRP20150064T1 HR P20150064 T1 HRP20150064 T1 HR P20150064T1 HR P20150064A T HRP20150064A T HR P20150064AT HR P20150064 T HRP20150064 T HR P20150064T HR P20150064 T1 HRP20150064 T1 HR P20150064T1
- Authority
- HR
- Croatia
- Prior art keywords
- insulin
- compound
- formula
- atoms
- combination
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims 22
- 102000004877 Insulin Human genes 0.000 title claims 11
- 108090001061 Insulin Proteins 0.000 title claims 11
- 229940125396 insulin Drugs 0.000 title claims 11
- 206010012601 diabetes mellitus Diseases 0.000 title claims 3
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- GFICWFZTBXUVIG-UHFFFAOYSA-N 6-n,6-n,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine Chemical compound CC1N=C(N)NC(N(C)C)=N1 GFICWFZTBXUVIG-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000014101 glucose homeostasis Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 238000009512 pharmaceutical packaging Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Pripravak za uporabu kao lijek koji sadrži inzulin u kombinaciji s barem jednim spojem formule (I) i/ili njegovim fiziološki prikladnim solima, gdje je spoj formule (I) definiran kako slijedi:
[image]
gdje
R1, R2 svaki, međusobno nezavisno, predstavljaju H ili A,
R3, R4 svaki, međusobno nezavisno, predstavljaju H, A, alkenil koji ima 2-6 C atoma, alkinil koji ima 2-6 C atoma, Ar ili Het,
R5, R6 svaki, međusobno nezavisno, predstavljaju H, A, (CH2)nAr, (CH2)mOAr, (CH2)mOA ili (CH2)mOH,
R5 i R6 zajedno također predstavljaju alkilen koji ima 2, 3, 4 ili 5 C atoma, gdje jedna CH2 skupina može biti zamijenjena s O, NH ili NA i/ili gdje se 1 H atom može zamijeniti s OH,
Ar predstavlja fenil, naftil ili bifenil, od kojih je svaki nesupstituiran ili je mono-, di- ili trisupstituiran s Hal, A, OA, OH, COOH, COOA, CN, NH2, NHA, NA2, SO2A i/ili COA,
Het predstavlja mono-, bi- ili triciklički zasićeni, nezasićeni ili aromatski heterocikl koji ima 1 do 4 N, O i/ili S atoma, koji mogu biti nesupstituirani ili mono-, di- ili trisupstituirani s Hal, A, OH, OA, NH2, (CH2)nAr, NHA, NA2, COOH, COOA i/ili =O (karbonil kisik),
A predstavlja nerazgranati ili razgranati alkil koji ima 1-10 C atoma, gdje 1-7 H atoma može biti zamijenjeno s F, ili ciklički alkil koji ima 3-7 C atoma,
Hal predstavlja F, Cl, Br ili I,
m je 1, 2, 3, 4, 5 ili 6, i
n je 0, 1 ili 2.
2. Farmaceutski pripravak koji kao djelatne tvari sadrži učinkovitu količinu inzulina u kombinaciji s učinkovitom količinom spoja formule (I) kako je definiran u zahtjevu 1 i/ili njegovih fiziološki prikladnih soli, zajedno s jednim ili više farmaceutski prikladnih adjuvansa.
3. Pripravak prema zahtjevu 1 ili 2, gdje je spoj formule (I) 2-amino-3,6-dihidro-4-dimetilamino-6-metil-1,3,5-triazin.
4. Pripravak prema bilo kojem od zahtjeva 1 do 3 za sprečavanje ili terapijsko liječenje i/ili praćenje bolesti koje su povezane s otpornošću na inzulin.
5. Pripravak prema zahtjevu 4, gdje se bolesti izabiru iz skupine koja obuhvaća dijabetes, pre-dijabetes, nisku toleranciju glukoze, hiperglikemiju, metabolički sindrom, dijabetičku nefropatiju, neuropatiju, retinopatiju, aterosklerozu i kardiovaskularne bolesti, poželjno o inzulinu ovisan dijabetes melitus i o inzulinu neovisan dijabetes melitus.
6. Pripravak prema bilo kojem od zahtjeva 1 do 5 za oralnu ili parenteralnu primjenu, poželjno u obliku otopine za injekciju za parenteralnu primjenu.
7. Pripravak prema bilo kojem od zahtjeva 1 do 6, gdje je inzulin u fiksnoj kombinaciji sa spojem formule (I) u jednom dozirnom obliku.
8. Pripravak prema bilo kojem od zahtjeva 1 do 6, gdje su inzulin i spoj formule (I) u odvojenim dozirnim oblicima u jednom pakiranju.
9. Uporaba inzulina u kombinaciji s barem jednim spojem formule (I) kako je definiran u zahtjevu 1 i/ili njegovim fiziološki prikladnim solima, za proizvodnju lijeka za sprečavanje ili terapijsko liječenje i/ili praćenje bolesti koje su povezane s otpornošću na inzulin.
10. Uporaba inzulina u kombinaciji s barem jednim spojem formule (I) kako je definiran u zahtjevu 1 i/ili njegovim fiziološki prikladnim solima za poboljšanje homeostaze glukoze.
11. Uporaba prema zahtjevu 9 ili 10, gdje se poboljšavaju tolerancija na glukozu i/ili izlučivanje inzulina kao odgovor na glukozu.
12. Uporaba prema bilo kojem od zahtjeva 9 do 11, gdje se spoj formule (I) daje za primjenu u rasponu doza od 25 do 200 mg po kilogramu tjelesne težine.
13. Uporaba prema bilo kojem od zahtjeva 9 do 12, gdje se inzulin i spoj formule (I) daju u oblicima za istovremenu ili uzastopnu primjenu.
14. Kombinacija učinkovite količine inzulina i učinkovite količine barem jednog spoja formule (I) kako je definiran u zahtjevu 1 i/ili njegovih fiziološki prikladnih soli, za uporabu u liječenju bolesti koje su povezane s otpornošću na inzulin.
15. Farmaceutsko pakiranje za sprečavanje ili terapijsko liječenje i/ili praćenje bolesti koje su povezane s otpornošću na inzulin, koje sadrži kao djelatne tvari učinkovitu količinu inzulina, zajedno s jednim ili više farmaceutski prikladnih adjuvansa, u prvom dozirnom obliku, i učinkovitu količinu barem jednog spoja formule (I) kako je definiran u zahtjevu 1 i/ili njegovih fiziološki prikladnih soli, zajedno s jednim ili više farmaceutski prikladnih adjuvansa, u drugom dozirnom obliku.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021617 | 2008-12-12 | ||
| EP09756258.1A EP2355829B1 (en) | 2008-12-12 | 2009-11-13 | Combination of insulin with triazine derivatives and its use for treating diabetes |
| PCT/EP2009/008099 WO2010066326A1 (en) | 2008-12-12 | 2009-11-13 | Combination of insulin with triazine derivatives and its use for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150064T1 true HRP20150064T1 (hr) | 2015-02-27 |
Family
ID=41566311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150064AT HRP20150064T1 (hr) | 2008-12-12 | 2015-01-19 | Kombinacija inzulina i derivata triazina te uporaba iste u lijeäśenju dijabetesa |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8592370B2 (hr) |
| EP (1) | EP2355829B1 (hr) |
| JP (1) | JP5667985B2 (hr) |
| KR (1) | KR101623819B1 (hr) |
| CN (1) | CN102245185A (hr) |
| AR (1) | AR074555A1 (hr) |
| AU (1) | AU2009326604B2 (hr) |
| BR (1) | BRPI0923373B8 (hr) |
| CA (1) | CA2746479C (hr) |
| CY (1) | CY1115973T1 (hr) |
| DK (1) | DK2355829T3 (hr) |
| EA (1) | EA021395B1 (hr) |
| ES (1) | ES2530223T3 (hr) |
| HR (1) | HRP20150064T1 (hr) |
| IL (1) | IL213421A (hr) |
| MX (1) | MX2011006073A (hr) |
| PL (1) | PL2355829T3 (hr) |
| PT (1) | PT2355829E (hr) |
| SG (1) | SG171986A1 (hr) |
| SI (1) | SI2355829T1 (hr) |
| SM (1) | SMT201500032B (hr) |
| WO (1) | WO2010066326A1 (hr) |
| ZA (1) | ZA201105094B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2577930T3 (es) * | 2010-06-09 | 2016-07-19 | Poxel | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 |
| TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| EP2790704B1 (en) * | 2011-12-12 | 2019-04-03 | Melior Pharmaceuticals I, Inc. | Treatment of type i diabetes |
| MX2020003243A (es) | 2017-10-02 | 2020-09-18 | Poxel | Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. |
| WO2019236844A1 (en) | 2018-06-06 | 2019-12-12 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| CN112218623A (zh) * | 2018-06-14 | 2021-01-12 | 博希尔公司 | 用于治疗糖尿病的包含三嗪衍生物的薄膜包衣片剂 |
| KR20220113942A (ko) | 2019-12-13 | 2022-08-17 | 스미토모 파마 가부시키가이샤 | 제조성 및 용출성이 우수한 소형 정제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172814A (en) * | 1962-04-06 | 1965-03-09 | Jr Edgar A Ferguson | Oral blood sugar lowering compositions |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| BR0206847A (pt) | 2001-02-02 | 2004-02-25 | Pfizer | Tratamento do diabete melito |
| DE10301788B4 (de) * | 2003-01-20 | 2005-08-25 | Aventis Pharma Deutschland Gmbh | Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen |
| FR2896159B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
-
2009
- 2009-11-13 SI SI200931123T patent/SI2355829T1/sl unknown
- 2009-11-13 BR BRPI0923373A patent/BRPI0923373B8/pt not_active IP Right Cessation
- 2009-11-13 KR KR1020117016022A patent/KR101623819B1/ko active IP Right Grant
- 2009-11-13 ES ES09756258.1T patent/ES2530223T3/es active Active
- 2009-11-13 MX MX2011006073A patent/MX2011006073A/es active IP Right Grant
- 2009-11-13 DK DK09756258.1T patent/DK2355829T3/en active
- 2009-11-13 WO PCT/EP2009/008099 patent/WO2010066326A1/en active Application Filing
- 2009-11-13 PT PT97562581T patent/PT2355829E/pt unknown
- 2009-11-13 JP JP2011539914A patent/JP5667985B2/ja active Active
- 2009-11-13 AU AU2009326604A patent/AU2009326604B2/en not_active Ceased
- 2009-11-13 US US13/139,027 patent/US8592370B2/en active Active
- 2009-11-13 EA EA201100916A patent/EA021395B1/ru not_active IP Right Cessation
- 2009-11-13 PL PL09756258T patent/PL2355829T3/pl unknown
- 2009-11-13 CA CA2746479A patent/CA2746479C/en active Active
- 2009-11-13 SG SG2011041175A patent/SG171986A1/en unknown
- 2009-11-13 EP EP09756258.1A patent/EP2355829B1/en active Active
- 2009-11-13 CN CN2009801495028A patent/CN102245185A/zh active Pending
- 2009-12-09 AR ARP090104757A patent/AR074555A1/es unknown
-
2011
- 2011-06-06 IL IL213421A patent/IL213421A/en active IP Right Grant
- 2011-07-11 ZA ZA2011/05094A patent/ZA201105094B/en unknown
-
2013
- 2013-07-15 US US13/941,677 patent/US8980828B2/en active Active
-
2015
- 2015-01-19 HR HRP20150064AT patent/HRP20150064T1/hr unknown
- 2015-01-30 CY CY20151100101T patent/CY1115973T1/el unknown
- 2015-02-11 SM SM201500032T patent/SMT201500032B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150064T1 (hr) | Kombinacija inzulina i derivata triazina te uporaba iste u lijeäśenju dijabetesa | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| HRP20191148T1 (hr) | Kombinirana terapija za liječenje dijabetesa | |
| JP2005520778A5 (hr) | ||
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| JP2014520864A5 (hr) | ||
| KR101878252B1 (ko) | 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물 | |
| CZ20032927A3 (cs) | Léčení cukrovky typu 2 inhibitory z dipeptidylpeptidázy IV | |
| JP2015519322A5 (hr) | ||
| HRP20240173T1 (hr) | Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| KR20110070919A (ko) | 스핑고신-１-포스페이트 수용체 길항제 및 항마이크로튜블 제제의 상승적 조합물 | |
| JP2020510043A5 (hr) | ||
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| CN105646512A (zh) | 一种列奈类小檗碱偶合物的制备及医药用途 | |
| Srivastava et al. | To evaluate the synergistic effect of Pinitol with Glimepride in diabetic Wistar rats | |
| US10543187B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| JP2023501967A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| CA2482687A1 (en) | Treatment of mesothelioma | |
| WO2023096854A1 (en) | Acetylcholine receptor agonists and methods of treating neurological disorders and neuropathic pain | |
| CN105777846A (zh) | 一种齐墩果酸小檗碱偶合物的制备方法及医药用途 | |
| JP2001288089A (ja) | ジアミノトリフルオロメチルピリジン誘導体を含有する肝疾患の治療剤又は予防剤 | |
| TH90121A (th) | วิธีสำหรับการป้องกันและการรักษาความผิดปกติทางเมแทบอลิซึม และอนุพันธ์ไพแรซอล-o-ไกลคอไซด์ตัวใหม่ |